Last updated: 13.02.2014

Address: Via Valosa di Sopra, 9 ,20900 – Monza – Italy

Tel: +39.039.7390.1


Company description

The group started its activities in 1961, when Luigi Rovati, founded in Monza (Italy) the Rotta Research
Laboratorium. Since then the company has always been focusing on research, innovation, development
and global distribution of new, mainly pharmaceutical products and extended the activities on para-pharmaceutical products later on.

The group’s traditional research fields in the gastrointestinal/digestive area and in the osteo-articular area have been extended, through intensive activity, to include the fields of hormone replacement therapy/women’s health/gynaecology and, more recently, the cardiovascular, respiratory tract and central nervous system areas.

In 2000, with the acquisition of Saugella and Babygella brands, Rottapharm entered the personal care sector, gaining the leadership in the market of personal hygiene products sold in pharmacies. At the same time, Rottapharm developed a nutraceutical product line, based on natural ingredients.
With the acquisition of Biochimici PSN in 2005, Rottapharm gained the leadership in the Personal Care through Pharmacy Channel, and the 6th position in Europe.

The groups headquarter and research center is in Monza, Italy with four manufacturing sites in Europe: Confienza (Italy), Dublin (Ireland), Wiehl (Germany)
and Lisbon (Portugal).

To date the intense research activity has generated over 4000 molecular hits, about 300 patents and 19 new drugs. Several new chemical entities are at an
advanced stage of research. Rottapharm produces and distributes well-known brands such as Dona, Ananase, Epinitril, Estromineral, Saugella and

Products and services

With the acquisition of 100% of the global German pharmaceutical company Madaus Pharma on August 2007, the Rottapharm Group, has become one of the leading companies focused on the development and distribution of natural pharmaceuticals.
This acquisition is the most important M&A operation ever completed by an Italian pharmaceutical company.

In 2006 Rottapharm reported revenues of 286 million euro and an EBITDA of 89 million euro (EBITDA margin equal to 31%). With the acquisition of Madaus Pharma, the new group has closed the fiscal year 2007 with consolidated revenues of around 550 million euro, and an EBITDA of 126 million euro.



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here